CN1198614C - pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 - Google Patents

pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 Download PDF

Info

Publication number
CN1198614C
CN1198614C CNB988063891A CN98806389A CN1198614C CN 1198614 C CN1198614 C CN 1198614C CN B988063891 A CNB988063891 A CN B988063891A CN 98806389 A CN98806389 A CN 98806389A CN 1198614 C CN1198614 C CN 1198614C
Authority
CN
China
Prior art keywords
inh
lps
amino
induced
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988063891A
Other languages
English (en)
Chinese (zh)
Other versions
CN1261278A (zh
Inventor
E·昆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of CN1261278A publication Critical patent/CN1261278A/zh
Application granted granted Critical
Publication of CN1198614C publication Critical patent/CN1198614C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB988063891A 1997-05-13 1998-05-13 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 Expired - Fee Related CN1198614C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US08/855,616 1997-05-13
US09/056,396 1998-04-06
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors

Publications (2)

Publication Number Publication Date
CN1261278A CN1261278A (zh) 2000-07-26
CN1198614C true CN1198614C (zh) 2005-04-27

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988063891A Expired - Fee Related CN1198614C (zh) 1997-05-13 1998-05-13 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法

Country Status (9)

Country Link
EP (1) EP1009404A4 (enExample)
JP (1) JP4362638B2 (enExample)
CN (1) CN1198614C (enExample)
AU (2) AU745790B2 (enExample)
BR (1) BR9809115A (enExample)
CA (1) CA2289119C (enExample)
IL (1) IL132758A0 (enExample)
NZ (1) NZ501650A (enExample)
WO (2) WO1998051308A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
ES2282410T3 (es) 2001-05-08 2007-10-16 Kudos Pharmaceuticals Limited Derivados de isoquinolinona como inhibidores de parp.
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
WO2006135873A2 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA026578B1 (ru) 2007-01-22 2017-04-28 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
MX2011003740A (es) 2008-10-07 2011-05-02 Astrazeneca Uk Ltd Formulacion farmaceutica - 514.
US8420668B2 (en) 2008-11-28 2013-04-16 Chugai Seiyaku Kabushiki Kaisha 1-(2H)-isoquinolone derivative
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
WO2018237327A1 (en) 2017-06-22 2018-12-27 Triact Therapeutics, Inc. Methods of treating glioblastoma
WO2019067991A1 (en) 2017-09-29 2019-04-04 Triact Therapeutics, Inc. INIPARIB FORMULATIONS AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004663A1 (en) 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
EP1009404A4 (en) 2009-07-01
AU745790B2 (en) 2002-03-28
JP2002502367A (ja) 2002-01-22
WO1998051307A1 (en) 1998-11-19
EP1009404A1 (en) 2000-06-21
CA2289119A1 (en) 1998-11-19
BR9809115A (pt) 2002-01-02
NZ501650A (en) 2001-11-30
CA2289119C (en) 2011-03-15
JP4362638B2 (ja) 2009-11-11
AU7484798A (en) 1998-12-08
AU7492698A (en) 1998-12-08
CN1261278A (zh) 2000-07-26
IL132758A0 (en) 2001-03-19
WO1998051308A1 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
CN1198614C (zh) pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US5908861A (en) Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6511800B1 (en) Methods of treating nitric oxide and cytokine mediated disorders
CN1160068C (zh) 脂蛋白氧化的抑制剂
CN101732298B (zh) 用sarms治疗良性前列腺增生
WO2014062621A1 (en) Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
CN103619168B (zh) 用于治疗白血病的组合物、方法和药盒
Wu et al. Targeting IRE1α improves insulin sensitivity and thermogenesis and suppresses metabolically active adipose tissue macrophages in male obese mice
US9693994B2 (en) Class IIa HDAC inhibitors for the treatment of infection
CN116492325A (zh) 以衣康酸为起点抑制Tet靶点蛋白的药物开发
EP2107907B1 (en) Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders
CN113082208B (zh) 阻断微生物感染、降低胆固醇、防治相关肿瘤的药物及其应用
Takeuchi et al. Nuclear factor-κB and TNF-α mediate gastric ulceration induced by phorbol myristate acetate
WO2020041308A1 (en) Compositions and methods for increasing beiging of white adipose tissue
WO2023198107A1 (en) Prevention and treatment of viral infection
Li et al. Oxypeucedanin attenuates neuropathic pain in male mice via inhibiting lysophosphatidic acid receptor signaling
MXPA99010417A (en) METHODS FOR TREATING INFLAMMATION AND INFLAMMATORY DISEASES USING pADPRT INHIBITORS
of Neurochemistry 2021 ASN Virtual Meeting Abstracts
Murray Synthetic Ligands Targeting ROR and REV-ERB to Treat Inflammatory and Metabolic Disease States
WO2022127788A1 (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
TW202402321A (zh) 一種第i型甲醯胜肽受體拮抗劑及其用途
Kandimalla et al. Venkateswara Reddy Gogulamudi1, Mohan Lal Dubey1, Deepak Kaul3, Donfack Jean Hubert4
HK1134032B (en) New combination for use in the treatment of inflammatory disorders
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050427

Termination date: 20170513

CF01 Termination of patent right due to non-payment of annual fee